Platelet-Activating Factor (PAF) Receptors

Antiplatelet agent 3 is a potent anti-platelet aggregation agent that inhibits platelet aggregation induced by ADP, AA, and COL, with IC50 values of 2.55, 3.22, and 2.09 mg/mL, respectively. This compound demonstrates significant biological activity advantageous for elucidating mechanisms involved in thrombosis and other cardiovascular conditions. Antiplatelet agent 3 is suitable for use in cardiovascular disease research, providing insights into therapeutic strategies for managing platelet-related disorders.

Lyso-PAF C-16 is a key precursor and metabolite of 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (PAF C-16). It serves as a substrate in the remodeling pathway for the formation of PAF C-16 and is also involved in the selective acylation with arachidonic acid through a CoA-independent transacylase. This compound is beneficial for research into lipid metabolism and the roles of bioactive lipids in various biological processes.

P11 is a selective inhibitor of platelet-activating factor acetylhydrolases (PAFAHs) 1b2 and 1b3, demonstrating significant impairment of cancer cell survival. With IC50 values of approximately 40 nM for PAFAH1b2 and 900 nM for PAFAH1b3, P11 is a valuable tool for investigating the role of these enzymes in cancer biology and related research applications, including studies focused on cell proliferation and apoptosis.

2-Thio-PAF is a synthetic analog of platelet-activating factor (PAF) that serves as a valuable tool for studying PAF metabolism. It effectively inhibits PAF acetylhydrolases, allowing researchers to assess enzyme activity through colorimetric assays. This compound is significant in investigating various biological processes influenced by PAF signaling, including inflammation and cellular responses.

Cloricromen is a potent platelet aggregation inhibitor that functions by targeting the mechanisms involved in thrombus formation. Demonstrating efficacy in inhibiting platelet aggregation in both human subjects and experimental models, Cloricromen is a valuable reagent for research in cardiovascular disease and thrombotic disorders. Its application in studying platelet function and related pathologies makes it an essential tool for investigations in vascular biology.

4-Trifluoromethylsalicylic acid, also known as Desacetyl triflusal, functions as a platelet aggregation inhibitor. This compound is instrumental in research related to cardiovascular disorders, particularly in the study of thrombus formation and prevention. Its ability to modulate platelet activity makes it a valuable tool for investigating hematological processes and developing antithrombotic therapies.

Imolamine is a potent antiplatelet aggregation agent that functions through the modulation of platelet activation pathways. As a phenyl aminoxidiazole derivative, it demonstrates significant anti-thrombotic activity, making it a valuable tool for studying platelet biology and associated disorders. This compound is relevant for research into coronary heart disease and other cardiovascular conditions where platelet aggregation plays a critical role.

Ataprost is a potent platelet aggregation inhibitor that functions as an orally active analogue of Carboprostacyclin. This compound demonstrates 2.6 times greater efficacy than Carboprostacyclin in inhibiting ADP-induced platelet aggregation in vitro. Additionally, Ataprost has been shown to alleviate coronary spasm, making it relevant for research in cardiovascular diseases and platelet function studies.

Evategrel is a potent platelet aggregation inhibitor that primarily targets ADP receptors on platelets. This compound effectively reduces thrombus formation, making it useful for research in cardiovascular diseases and the study of clotting mechanisms. Its ability to modulate platelet activity supports investigations into antiplatelet therapies and their applications in preventing thrombotic events.

Prostaglandin I3 sodium is a potent inhibitor of platelet aggregation, primarily acting through the stimulation of adenylate cyclase, which increases cyclic AMP levels in platelets. This compound also exhibits vasodilatory properties, making it useful in studies related to cardiovascular health and thrombotic disorders. Its applications include research into the modulation of vascular tone and the prevention of platelet-related complications in various disease models.

[Rh(cod)Cl]2 (Chloro(1,5-cyclooctadiene)rhodium(I) dimer) functions as an anti-platelet aggregation agent by inhibiting platelet-activating factor-mediated aggregation, with IC50 values of 5.2 μM in rabbit platelets and 43.3 μM in human platelet-rich plasma. It also inhibits thrombin-, ADP-, and collagen-induced aggregation, showing IC50 values of 16.7 μM, 162 μM, and 69.8 μM, respectively. This compound is valuable for research into cardiovascular diseases, particularly thrombosis.

Cloricromen hydrochloride is a potent platelet aggregation inhibitor that effectively targets and modulates platelet activation pathways. This compound has demonstrated the ability to inhibit platelet aggregation in both human and experimental thrombosis models, making it a valuable reagent for research into cardiovascular diseases and thrombotic disorders. Cloricromen hydrochloride is suitable for studies focused on the mechanisms of platelet function and the development of antithrombotic therapies.

KP-10614 is a potent, orally active inhibitor of platelet aggregation, primarily targeting ADP-induced aggregation with an IC50 of 1 nM. This compound exhibits dose-dependent inhibition of ex vivo platelet aggregation in rat models. KP-10614 demonstrates significant antithrombotic effects across various thrombosis models, making it a valuable tool for research into thrombotic diseases.